长春高新：关于子公司注射用GenSci136境内生产药品注册临床试验申请获得受理的公告

Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the clinical trial application of GenSci136 injection, marking a significant step in the drug registration process [2] Group 1 - The acceptance notice indicates that the clinical trial application for GenSci136 has been officially recognized by regulatory authorities [2] - This development may enhance the company's product pipeline and potential market offerings in the pharmaceutical sector [2] - The approval process reflects the company's commitment to advancing its research and development initiatives [2]